UNSPSC 51472807: Chlorhexidine hydrochloride

This classification denotes a topical anti-infective agent with the molecular structure C22H30CL2N10.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, E64XL9U38K chemically known as 1,1'-hexamethylenebis(5-(p-chlorophenyl)biguanide)dihydrochloride, but more commonly known as chlorhexidine hydrochloride, which bears US NIH Compound Identifier 9571016. European Medicines Agency schedules Chlorhexidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01216MIG.

UNSPSC 51472807 Chlorhexidine hydrochloride, a Commodity code, covers antimicrobial and disinfectant chemical products that state and local governments procure as consumable supplies for healthcare facilities, fire departments, correctional institutions, and other public operations requiring infection control or sanitization. Recent solicitations show the code being used for pharmaceutical and OTC products bundled into larger janitorial, operational, and medical supply contracts where chlorhexidine-based products are components of broader consumable purchasing agreements rather than standalone line items. Issuing bodies include county purchasing offices and state cooperative purchasing alliances, with activity driven by operating agencies such as fire rescue departments and state health systems that require reliable supplies on recurring, as-needed bases.

Recent opportunities span multiple states and procurement models. Hillsborough County Board of County Commissioners in Florida posted ITB 2600319 on July 7, 2026, for consumable janitorial and operational supplies for its Fire Rescue Department, with bids due July 24, 2026 and an estimated contract value of $765,679.84 for one year. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Both opportunities emphasize authorized wholesaler distribution, product compliance (FDA requirements, cGMP, DSCSA certification), and performance metrics tied to delivery timelines and reporting accuracy.